Allogene Therapeutics is approaching a preliminary readout from a clinical study that could provide crucial validation for its off-the-shelf CAR-T cancer treatment approach. The biotech company has maintained confidence in its manufacturing strategy despite industry skepticism.
CAR-T therapies traditionally require personalized manufacturing using a patient's own immune cells, a process that can take weeks and costs hundreds of thousands of dollars. Allogene's approach aims to create ready-made treatments from donor cells that could be immediately available to patients.